Pharma D-mand

Whether you're working in analytical development, quality assurance, or regulatory affairs, subvisible particle analysis deserves strategic consideration for ensuring product safety throughout development. The key lies in accessing actionable guidance from experts who understand both the analytical science and regulatory realities. Coriolis Pharma's "Subvisible Particle Analysis: Ensuring Quality from Lab Bench to GMP" will provide exactly that, featuring insights from Dr. Bodo Brocks, Quality Unit Manager and Dr. Sergey Sotnikov, Principal Scientist GMP, drawing on decades of analytical development and validation experience. 📅 November 18, 2025 ⏰ 16:00 CET | 10:00 ET  🔗 Register today: https://lnkd.in/eMRawVf5 How are you currently approaching analytical method lifecycle management for your key methods? #CoriolisPharma #PharmaDmand #AnalyticalStrategy #MethodLifecycle #QualityAssurance 

Identifying viable candidates for nasal repositioning requires balancing scientific rationale with commercial feasibility. Understanding absorption potential, CNS access opportunities, and unmet patient needs can transform your approach to existing portfolios. Reenal Gandhi and Julie Suman, PhD will share practical evaluation frameworks in Aptar Pharma's "Unlocking Therapeutic Potential Through Nasal Drug Repositioning" webinar. 📅 November 13, 2025   ⏰ 16:00 CET | 10:00 ET  🔗 Secure your place: https://lnkd.in/eRff5Nb3 What criteria do you use when assessing repositioning potential for your APIs? #AptarPharma #PharmaDmand #PortfolioOptimisation #DrugDevelopment #CommercialViability 

Strategic method evaluation is essential before committing to a GMP validation pathway. Understanding how to balance analytical precision with regulatory feasibility can make the difference between success and costly validation failures. Join Coriolis Pharma's "Subvisible Particle Analysis: Ensuring Quality from Lab Bench to GMP" where Dr. Bodo Brocks and Dr. Sergey Sotnikov discuss how to: • Balance analytical precision with regulatory feasibility  • Navigate complex validation pathways for particle analysis  • Select optimal analytical systems for GMP environments 📅 November 18, 2025  ⏰ 16:00 CET | 10:00 ET 🔗 Save your seat: https://lnkd.in/eMRawVf5 Which factors do you prioritise when evaluating analytical method candidates? #CoriolisPharma #PharmaDmand #RegulatoryAffairs #MethodDevelopment #AnalyticalValidation 

Whether you're working in portfolio strategy, clinical development, or commercial planning, nasal repositioning deserves strategic consideration for extending product lifecycles. The key lies in accessing actionable guidance from experts who understand both the science and business realities. Aptar Pharma's "Unlocking Therapeutic Potential Through Nasal Drug Repositioning" will provide exactly that, featuring insights from Reenal Gandhi and Julie Suman, drawing on decades of drug delivery and commercialisation experience. 📅 November 13, 2025   ⏰ 16:00 CET | 10:00 ET  🔗 Register today: https://lnkd.in/eRff5Nb3 How are you currently approaching lifecycle management for your key assets? #AptarPharma #PharmaDmand #PortfolioStrategy #ProductLifecycle #BusinessDevelopment 

Strategic evaluation is essential before committing to a repositioning pathway. Understanding how to balance scientific rationale with commercial feasibility can make the difference between success and costly missteps. Join Aptar Pharma's "Unlocking Therapeutic Potential Through Nasal Drug Repositioning" where Reenal Gandhi and Julie Suman, PhD, will explain how to: • Balance scientific rationale with commercial feasibility   • Navigate complex regulatory pathways for new indications   • Select optimal nasal delivery systems for repositioned therapies 📅 November 13, 2025   ⏰ 16:00 CET | 10:00 ET  🔗 Save your seat: https://lnkd.in/eRff5Nb3 Which factors do you prioritise when evaluating repositioning candidates? #AptarPharma #PharmaDmand #RegulatoryAffairs #CommercialStrategy #PharmaInnovation 

Happening tomorrow – Don't miss this expert-led discussion from Upperton on ‘Nose-to-Brain Drug Delivery and Device Selection’. Richard Johnson and Lara Penn will share actionable guidance on achieving effective CNS delivery through the nasal route—from aligning formulation and device parameters to designing data-driven development programmes that support regulatory progress. This is your final opportunity to join the conversation and gain insight into the technical foundations of successful nose-to-brain therapies. 🗓 1 October 2025  🕒 15:00 BST | 10:00 ET  🔗 https://lnkd.in/e8tQ2ifG What are you hoping to take away from the session? #Upperton #PharmaDmand #FormulationScience #PulmonaryDelivery #DrugDevelopment 

When traditional analytical methods limit your product's quality assurance potential, you need a validation strategy that works around those barriers. In Coriolis Pharma's webinar, "Subvisible Particle Analysis: Ensuring Quality from Lab Bench to GMP", Dr. Bodo Brocks, Quality Unit Manager and Dr. Sergey Sotnikov, Principal Scientist GMP will explain how precise particle analysis can provide enhanced method robustness and regulatory compliance. 📅 November 18, 2025  ⏰ 16:00 CET | 10:00 ET  🔗 Reserve your place: https://lnkd.in/eMRawVf5 What analytical limitations are restricting your method's validation potential? #CoriolisPharma #PharmaDmand #MethodRobustness #AnalyticalScience #PharmaceuticalQuality 

With just one week to go, this is the time to secure your spot for Upperton Pharma Solutions’ ‘Nose-to-Brain Drug Delivery and Device Selection’ webinar. They’ll be offering practical insights for those developing nasal products aimed at the central nervous system. Richard Johnson will explore how spray behaviour and device mechanics influence deposition and efficacy, while Lara Penn will outline formulation and testing strategies that help bridge lab data with real-world delivery performance. 🗓 1 October 2025  🕒 15:00 BST | 10:00 ET  🔗 https://lnkd.in/e8tQ2ifG Will you be joining live, or catching the replay on-demand? Let us know! #Upperton #PharmaDmand #INDrugDelivery #OlfactoryTargeting #DrugDeliveryDevices 

For pharmaceutical products facing particulate contamination risks or seeking enhanced analytical precision, subvisible particle analysis offers a scientifically robust pathway that can accelerate method validation and expand quality assurance capabilities. This evidence-based approach will be explored in depth during "Subvisible Particle Analysis: Ensuring Quality from Lab Bench to GMP", where Dr. Bodo Brocks, Quality Unit Manager and Dr. Sergey Sotnikov, Principal Scientist GMP from Coriolis Pharma will focus on transforming analytical methods into validated quality control systems. 📅 November 18, 2025  ⏰ 16:00 CET | 10:00 ET 🔗 Register here: https://lnkd.in/eMRawVf5 How could enhanced particle analysis revolutionise your current quality control approach? #CoriolisPharma #PharmaDmand #AnalyticalDevelopment #RegulatoryCompliance #MethodValidation 

When traditional delivery routes limit your molecule's potential, you need a repositioning strategy that works around those barriers. In Aptar Pharma's webinar, "Unlocking Therapeutic Potential Through Nasal Drug Repositioning", Reenal Gandhi and Julie Suman, PhD will explain how nasal delivery can provide enhanced bioavailability and patient access. 📅 November 13, 2025   ⏰ 16:00 CET | 10:00 ET 🔗 Reserve your place: https://lnkd.in/eRff5Nb3  What delivery challenges are limiting your API's therapeutic potential? #AptarPharma #PharmaDmand #Bioavailability #FormulationStrategy #AdvancedDrugDelivery